Partner with Biogen
Making breakthroughs happen together
Biogen sits at the epicenter of bold scientific discovery and the partnerships that are redefining what's possible in healthcare. Together, we can potentially transform breakthrough science into global commercial success.
Biotech roots, global pharma resources
Biogen has a nearly 50-year legacy of tackling the most complex diseases, combining biotech agility with global pharma capabilities.
Every external partnership becomes a core part of our business, and we are deeply committed to its success, giving it the hands-on, personalized attention from our senior leaders and resources it deserves. Connect with us at partnering@biogen.com
Our unique approach to collaboration
Mission rooted
Partnerships are fundamental to how we discover, develop and deliver the next generation of medicines
Supporting partnerships at scale
Dedicating the right capital and the right organizational structures to each program
Open innovation model
Prioritizing innovation for patients, whether it is discovered internally, externally or in collaboration with partners
Diverse deal structures
Open to a variety of partnership structures, uniquely tailored for each opportunity, and now including equity investments with Biogen New Ventures
Areas of opportunity
Redefining what’s possible across our portfolio
We seek strategic partners who share our vision of transforming patient lives through breakthrough science across our core focus areas:
Biogen continues to leverage its historical strength and expertise in neuroscience and will continue to seek partnerships in areas of severe neurodegenerative, neuromuscular and neurodevelopmental diseases.
Our areas of interest include:
- Alzheimer’s disease and dementia
- Parkinson’s disease
- Huntington’s disease
- Spinal muscular atrophy
- Amyotrophic lateral sclerosis
- Friedreich ataxia
- Duchenne muscular dystrophy
- Myotonic dystrophy
- Dravet syndrome
- Angelman syndrome
- Epilepsies
- Multiple sclerosis
Leveraging decades of MS expertise to pioneer next-generation immune-mediated therapies in disease areas where we see significant untapped potential.
Our areas of interest include:
- Lupus
- Sjogren’s disease
- Grave’s disease
- Myasthenia Gravis
- Atopic dermatitis
- Alopecia areata
- Hidradenitis suppurativa
- Allergy
- IBD
Expanding on our immunology and clinical development expertise to advance investigational, immune-targeted therapies for kidney diseases with serious unmet need.
Our areas of interest include:
- AMR
- IgAN
- PMN
- Focal Segmental Glomerulosclerosis (FSGS)
- C3 Glomerulopathies (C3G)
- Alport Syndrome
- Transplant rejection
Applying our proven commercial model in areas that intersect our deep scientific expertise in CNS and the immune system.
Our areas of interest include:
- Rare cardiology
- Rare hematology
- Rare metabolic
- Rare diseases with prevalence 1-9/100,000 or greater and with significant unmet need and a clear path to patient identification and treatment
Building on our expertise with ASOs, small molecules, large molecules and biologics, and exploring new opportunities including platform technologies that enhance our pipeline.
Our areas of interest include:
- Nucleic acid therapeutics (siRNA, mRNA)
- Delivery technologies
- Traditional and next generation chemistry technologies (covalent, proximity-induced, AI-enabled, etc.)
- Traditional and next generation engineered biologics
Meet our team
BD and New Ventures
Adam Feire, Ph.D.
Biogen BD Europe
Yves Wyckmans
New Ventures
Chelsea Johnson
Transactions
Kevin Bromby
Search & Evaluation, New Areas
Laura Blumberg, Ph.D.
Search & Evaluation, Neuroscience
Catherine Abbadie, Ph.D.
Search & Evaluation, Immunology
Paul Andrews, Ph.D.
Our partnerships in action
HI-Bio
"I’m hard-pressed to find another example of an acquisition integration that’s gone as well as it has. We were able to move our program forward and continue to grow the programs beyond what we had started to do at HI-Bio. We created a vibrant, immunology-focused West Coast hub. It was fantastic to have a company that right away wanted to advance all three programs into Phase III at the same time.”
Travis Murdoch, Former CEO of HI-Bio and current CEO of Braveheart Bio
Neomorph
"Biogen came with a bold vision for how our cutting-edge platform could unlock historically undruggable targets in Alzheimer's, rare neurological and immunological diseases. What impressed us was not only their legacy in neurology, but their deep biological understanding of these complex diseases combined with their willingness to embrace emerging modalities. Biogen is not just funding innovation; they're accelerating it."
Phil Chamberlain, DPhil, Co-Founder, President and CEO, Neomorph
Some of our current partners
